146 related articles for article (PubMed ID: 10789595)
1. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer.
Hubert A; Lyass O; Pode D; Gabizon A
Anticancer Drugs; 2000 Feb; 11(2):123-7. PubMed ID: 10789595
[TBL] [Abstract][Full Text] [Related]
2. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
Gabizon AA
Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
[TBL] [Abstract][Full Text] [Related]
4. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y
Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389
[TBL] [Abstract][Full Text] [Related]
5. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.
Lotem M; Hubert A; Lyass O; Goldenhersh MA; Ingber A; Peretz T; Gabizon A
Arch Dermatol; 2000 Dec; 136(12):1475-80. PubMed ID: 11115157
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
7. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.
Hamilton A; Biganzoli L; Coleman R; Mauriac L; Hennebert P; Awada A; Nooij M; Beex L; Piccart M; Van Hoorebeeck I; Bruning P; de Valeriola D
Ann Oncol; 2002 Jun; 13(6):910-8. PubMed ID: 12123337
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
9. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer.
Tejada-Berges T; Granai CO; Gordinier M; Gajewski W
Expert Rev Anticancer Ther; 2002 Apr; 2(2):143-50. PubMed ID: 12113236
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma.
Skubitz KM
Cancer Invest; 2002; 20(5-6):693-9. PubMed ID: 12197225
[TBL] [Abstract][Full Text] [Related]
13. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
Uziely B; Jeffers S; Isacson R; Kutsch K; Wei-Tsao D; Yehoshua Z; Libson E; Muggia FM; Gabizon A
J Clin Oncol; 1995 Jul; 13(7):1777-85. PubMed ID: 7602367
[TBL] [Abstract][Full Text] [Related]
14. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
Coukell AJ; Spencer CM
Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma.
Skubitz KM
Cancer Invest; 2003 Apr; 21(2):167-76. PubMed ID: 12743981
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.
Matsumura Y; Gotoh M; Muro K; Yamada Y; Shirao K; Shimada Y; Okuwa M; Matsumoto S; Miyata Y; Ohkura H; Chin K; Baba S; Yamao T; Kannami A; Takamatsu Y; Ito K; Takahashi K
Ann Oncol; 2004 Mar; 15(3):517-25. PubMed ID: 14998859
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
Muggia FM; Hainsworth JD; Jeffers S; Miller P; Groshen S; Tan M; Roman L; Uziely B; Muderspach L; Garcia A; Burnett A; Greco FA; Morrow CP; Paradiso LJ; Liang LJ
J Clin Oncol; 1997 Mar; 15(3):987-93. PubMed ID: 9060537
[TBL] [Abstract][Full Text] [Related]
19. Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer.
Harris KA; Harney E; Small EJ
Clin Prostate Cancer; 2002 Jun; 1(1):37-41. PubMed ID: 15046711
[TBL] [Abstract][Full Text] [Related]
20. A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma.
Halford S; Yip D; Karapetis CS; Strickland AH; Steger A; Khawaja HT; Harper PG
Ann Oncol; 2001 Oct; 12(10):1399-402. PubMed ID: 11762810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
